Imran Ahmad

Imran Ahmad
University of Glasgow | UofG · The Beatson Institute for Cancer Research

PhD, FRCS (Urol), FEBU

About

139
Publications
8,802
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
1,767
Citations
Introduction
Clinical Senior Lecturer & CRUK Clinician Scientist at the CRUK: Beatson Institute/University of Glasgow. Honorary Consultant Urological & Robotic Surgeon at NHS Greater Glasgow & Clyde
Additional affiliations
August 2011 - present
University of Glasgow
August 2007 - present

Publications

Publications (139)
Article
Importance: Robot-assisted radical cystectomy is being performed with increasing frequency, but it is unclear whether total intracorporeal surgery improves recovery compared with open radical cystectomy for bladder cancer. Objectives: To compare recovery and morbidity after robot-assisted radical cystectomy with intracorporeal reconstruction vs...
Article
Full-text available
Background: The accuracy of multi-parametric MRI (mpMRI) in the pre-operative staging of prostate cancer (PCa) remains controversial. Objective: The purpose of this study was to evaluate the ability of mpMRI to accurately predict PCa extra-prostatic extension (EPE) on a side-specific basis using a risk-stratified 5-point Likert scale. This study al...
Preprint
Background Robotic radical prostatectomy (RARP) is a first-line curative treatment option for localized prostate cancer. Postoperative erectile dysfunction and urinary incontinence are common associated adverse side effects that can negatively impact patients’ quality of life. Preserving the lateral neurovascular bundles (NS) during RARP improves f...
Preprint
Full-text available
The accuracy of multi-parametric MRI (mpMRI) in pre-operative staging of prostate cancer (PCa) remains controversial. Objective: To evaluate the ability of mpMRI to accurately predict PCa extra-prostatic extension (EPE) on a side-specific basis using a risk-stratified 5-point Likert scale. This study also aimed to assess the influence of mpMRI scan...
Article
Objectives: To test feasibility of randomisation to radical prostatectomy plus pelvic lymphadenectomy (RP) in addition to standard-of-care (SOC) systemic therapy in men with newly diagnosed oligo-metastatic prostate cancer. Patients and methods: A prospective, randomised, non-blinded, feasibility clinical trial with an embedded QuinteT Recruitme...
Article
Full-text available
Background Pelvic nodal metastasis in prostate cancer impacts patient outcome negatively. Objective To explore tumor-infiltrating immune cells as a potential predictive tool for regional lymph node (LN) metastasis. Design, setting, and participants We applied multiplex immunofluorescence and targeted transcriptomic analysis on 94 radical prostate...
Article
Full-text available
Objectives: The purpose of this study was to investigate localised prostate cancer treated with or without neoadjuvant androgen deprivation therapy prior to robot-assisted laparoscopic prostatectomy, and the impact of Covid-19 treatment disruption, on clinico-pathologic outcomes. Patients and methods: Data was retrospectively collected from 124 co...
Article
Full-text available
Peroxisome Proliferator-Activated Receptor Gamma (PPARG) is one of the three members of the PPAR family of transcription factors. Besides its roles in adipocyte differentiation and lipid metabolism, we recently demonstrated an association between PPARG and metastasis in prostate cancer. In this study a functional effect of PPARG on AKT serine/threo...
Article
TPS262 Background: Robot-assisted radical prostatectomy (RARP) offers cure for localised prostate cancer but is associated with considerable toxicity. Potency and urinary continence are improved when the neurovascular bundles (NVBs) are preserved during a nerve-sparing (NS) RARP. The NeuroSAFE (intra-operative frozen section examination of the neur...
Article
Full-text available
COVID-19 has resulted in the deferral of major surgery for genitourinary (GU) cancers with the exception of cancers with high risk of progression. We report outcomes for major GU cancer operations, namely radical prostatectomy (RP), radical cystectomy (RC), radical nephrectomy (RN), partial nephrectomy (PN), and nephroureterectomy performed at 13 m...
Article
Full-text available
Background Multiparametric magnetic resonance imaging (mpMRI) is now recommended prebiopsy in numerous healthcare regions based on the findings of high-quality studies from expert centres. Concern remains about reproducibility of mpMRI to rule out clinically significant prostate cancer (csPCa) in real-world settings. Objective To assess the diagno...
Article
Full-text available
The characterization of prostate epithelial hierarchy and lineage heterogeneity is critical to understand its regenerative properties and malignancies. Here, we report that the transcription factor RUNX1 marks a specific subpopulation of proximal luminal cells (PLCs), enriched in the periurethral region of the developing and adult mouse prostate, a...
Article
Introduction: The BRG1/BRM associated factors (BAF) complex is a chromatin remodeling SWI/SNF which is mutated in 20% of cancers. This complex has many interchangeable subunits which may have oncogenic or tumor suppressor activity in a context-dependent manner. The BAF complex is mutated in 35-50% of metastatic prostate cancer (PC); however, its r...
Article
Full-text available
Background Clinical outcomes from non–muscle-invasive bladder cancer (NMIBC) are partly determined by the quality of initial interventions. To improve and standardise treatment for cancer, Scotland implemented a national Quality Performance Indicator (QPI) programme for bladder cancer (BC). Objective To evaluate compliance with specific quality in...
Article
Abstract Background: Clinical outcomes from non-muscle-invasive bladder cancer (NMIBC) are partly determined by the quality of initial interventions. To improve and standardise treatment for cancer, Scotland implemented a national Quality Performance Indicator (QPI) programme for bladder cancer (BC). Objective: To evaluate compliance with specific...
Preprint
Full-text available
The development of castration-resistant prostate cancer is a major complication of androgen-deprivation therapy. However, the origin and identity of these resistant cells remains controversial. Here, we report that the transcription factor RUNX1 marks a specific subpopulation of proximal luminal cells (PLCs), enriched in the periurethral region of...
Article
Full-text available
Brief Report of the NeuroSAFE PROOF Feasibility RCT with histological and peri-operative characterisation.
Article
Full-text available
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Article
Full-text available
BRF1 is a rate-limiting factor for RNA Polymerase III-mediated transcription and is elevated in numerous cancers. Here, we report that elevated levels of BRF1 associate with poor prognosis in human prostate cancer. In vitro studies in human prostate cancer cell lines demonstrated that transient overexpression of BRF1 increased cell proliferation wh...
Article
Inhibition of the androgen receptor (AR) is the main strategy to treat advanced prostate cancers. AR-independent treatment-resistant prostate cancer is a major unresolved clinical problem. Prostate cancer patients with alterations in canonical WNT pathway genes, which lead to β-catenin activation, are refractory to AR-targeted therapies. Here using...
Chapter
Prostate cancer (PCa) is the most common urological cancer and accounts for nearly a quarter of all new cancers in men. Since the widespread use of prostate‐specific antigen (PSA) testing in the 1990s, the incidence of PCa has risen sharply, but overall mortality from PCa has remained static. All areas of PCa from diagnosis through to surgical and...
Data
Source Data for Expanded View and Appendix
Article
Full-text available
Metastatic castration-resistant prostate cancer (mCRPC) is a lethal form of treatment-resistant prostate cancer and poses significant therapeutic challenges. Deregulated receptor tyrosine kinase (RTK) signalling mediated by loss of tumour suppressor Sprouty2 (SPRY2) is associated with treatment resistance. Using pre-clinical human and murine mCRPC...
Article
The link between prostate cancer (PC) development and lipid metabolism is well established, with AR intimately involved in a number of lipogenic processes involving SREBP1, PPARG, FASN, ACC, ACLY and SCD1. Recently, there is growing evidence implicating the role of obesity and peri-prostatic adipose tissue (PPAT) in PC aggressiveness and related mo...
Article
Recent next-generation-sequencing studies demonstrate that multiple pathways are often deregulated in advanced and metastatic prostate cancer (PC). In a recent issue of The Journal of Pathology, an elegant study by Jefferies et al used in vivo modelling to demonstrate how activation of the PI3K, WNT and MAPK pathway converges on mTORC1 signalling t...
Article
Full-text available
Extracellular signal-regulated protein kinase 5 (ERK5) has been implicated during development and carcinogenesis. Nkx3.1-mediated Cre expression is a useful strategy to genetically manipulate the mouse prostate. While grossly normal at birth, we observed an unexpected phenotype of spinal protrusion in Nkx3.1:Cre;Erk5fl/fl (Erk5fl/fl) mice by ~6–8 w...
Article
Full-text available
Prostate cancer (PCa) does not appear to respond to immune checkpoint therapies where T cell infiltration may be a key limiting factor. Here we report evidence that ablating the growth regulatory kinase Erk5 can increase T cell infiltration in an established Pten-deficient mouse model of human PCa. Mice that were doubly mutant in prostate tissue fo...
Article
Full-text available
Background: Obesity and aggressive prostate cancer (PC) may be linked, but how local peri-prostatic fat relates to tumour response following androgen deprivation therapy (ADT) is unknown. Objective: To test if peri-prostatic fat volume (PPFV) predicts tumour response to ADT. Design, setting, and participants: We performed a retrospective study...
Article
Full-text available
The widespread availability of PSA testing in the late 80s to early 90s subsequently led to questions being asked regarding its suitability in mass screening for the early detection of prostate cancer (PC). The low specificity of PSA for PC in the lower PSA ranges has resulted in over-investigation, and over-diagnosis of indolent cancers, leading t...
Article
Full-text available
Prostate cancer (CaP) is the most common adult male cancer in the developed world. The paucity of biomarkers to predict prostate tumor biology makes it important to identify key pathways that confer poor prognosis and guide potential targeted therapy. Using a murine forward mutagenesis screen in a Pten-null background, we identified peroxisome prol...
Article
Background: Robot-assisted radical cystectomy with intracorporeal urinary diversion (iRARC) is an attractive option to open cystectomy, but the benefit in terms of improved outcomes is not established. Objective: To evaluate the early postoperative morbidity and mortality of patients undergoing iRARC and conduct a critical analysis of complicati...
Article
Full-text available
Venturing into the world of laboratory-based research can be an extremely rewarding but also daunting step for clinicians. Combining our everyday clinical practice with cutting-edge laboratory research bridges our understanding of the basis of disease processes, and we can play a key role in translating such knowledge into better treatment for pati...
Article
Background: Patients undergoing radical cystectomy have associated comorbidities resulting in reduced cardiorespiratory fitness. Preoperative cardiopulmonary exercise testing (CPET) measures including anaerobic threshold (AT) can predict major adverse events (MAE) and hospital length of stay (LOS) for patients undergoing open and robotic cystectom...
Article
Full-text available
Urothelial cell carcinoma (UCC) of the bladder is one of the most common malignancies, causing considerable morbidity and mortality worldwide. It is unique among the epithelial carcinomas as two distinct pathways to tumourigenesis appear to exist: low grade, recurring papillary tumours usually contain oncogenic mutations in FGFR3 or HRAS whereas hi...
Article
Full-text available
Depletion of cellular energy activates the AMP-activated protein kinase (AMPK) to favor energy-producing catabolic processes during tumorigenesis. Using a panel of in vitro cell lines and resected tumors, we investigated the therapeutic value of manipulating AMPK in prostate cancer (PC). Phospho-AMPK expression was significantly elevated in human P...
Article
Full-text available
Although somatic mutations and overexpression of the tyrosine kinase Fibroblast Growth Factor Receptor 3 (FGFR3) are strongly associated with bladder cancer, evidence for their functional involvement in the pathogenesis remains elusive. Previously we showed that activation of Fgfr3 alone is not sufficient to initiate urothelial tumourigenesis in mi...
Article
Full-text available
Introduction The RNA-binding protein hnRNPA2 (HNRNPA2B1) is upregulated in cancer, where it controls alternative pre-mRNA splicing of cancer-relevant genes. Cytoplasmic hnRNPA2 is reported in aggressive cancers, but is functionally uncharacterized. We explored the role of hnRNPA2 in prostate cancer (PCa). Methods: hnRNPA2 function/localization/exp...
Article
Full-text available
Percutaneous renal access for percutaneous nephrolithotomy (PCNL) can be performed by either an interventional radiologist or urologist, depending on local expertise. We reviewed the current literature comparing the success and complications in gaining percutaneous access for both groups. An extensive literature search was carried out using Medline...
Article
Full-text available
Androgen-deprivation therapy (ADT) is standard treatment for locally advanced or metastatic prostate cancer (PCa). Many patients develop castration resistance (castration-resistant PCa [CRPC]) after approximately 2-3 yr, with a poor prognosis. The molecular mechanisms underlying CRPC progression are unclear. To undertake quantitative tumour transcr...
Article
Full-text available
Introduction: Tissue cryoablation is a potential curative option for solid malignancies, including radiation recurrent prostate cancer (RRPC). Case series of salvage cryotherapy (SCT) in RRPC have reported promising disease free survival (DFS) outcomes and acceptable toxicity profile. While many men receive SCT, no predictive factors for treatment...
Data
Data on pre and post-SCT nadir PSA levels for each of the three participating centres. (GLA – Glasgow, SUN – Sunderland, GUIL – Guildford.). (TIF)
Data
Breakdown of patient numbers for individual survival analysis in Figure 2 . (TIF)
Data
Pre and (3-month) post-SCT IPSS levels for the Glasgow cohort. (TIF)
Data
Gleason scores of radiation recurrent prostate cancer prior to SCT are shown for each the three centres. (GLA – Glasgow, SUN – Sunderland, GUIL – Guildford.). (TIF)